DACH Region Emerges as Clinical Trial Hub Despite EU's Strict Medical Device Regulations
核心洞察
Despite stringent EU medical device regulations, the DACH region (Germany, Austria, Switzerland) remains an attractive destination for clinical trials, with Switzerland's independent regulator Swissmedic (搜索) offering unique advantages.
New EU Medical Device Regulation (MDR) poses challenges for smaller companies and innovative trial designs, pushing some feasibility studies toward the US market.
The region faces recruitment challenges but shows promise through strategic site selection and potential for improved patient identification using real-world evidence.
Industry leaders have highlighted the DACH region's enduring appeal for clinical trials, despite challenges posed by stringent European Union (搜索) regulations, particularly for medical device and pharmaceutical companies. The insights emerged during a panel discussion at the 7th Annual Outsourcing in Clinical Trials DACH 2024 conference in Zurich, Switzerland.
Regulatory Landscape and Challenges
The implementation of the EU's Medical Device Regulation (MDR) in 2017 has created significant hurdles for smaller companies and innovative trial designs. Andrea Sauerland, senior vice-president of clinical operations at Endotronix (搜索), noted that conducting smaller feasibility trials with new devices has become increasingly challenging in Europe compared to the United States.
"Doing smaller trials like feasibility with new devices is becoming more difficult. It is more attractive for smaller companies to do [feasibility studies] in the US than in Europe, which was different 8-10 years ago," Sauerland explained.
Switzerland's Strategic Advantage
Despite these challenges, Switzerland's position as an independent regulatory jurisdiction offers distinct advantages. Ina Meyer, study and site operations country manager for Switzerland at Novartis, emphasized that Swissmedic (搜索), Switzerland's independent health authority, provides unique opportunities for expedited study initiation.
"Swissmedic (搜索) is keen on FDA feedback and the same with the EMA [European Medicines Agency]. As own health authority, and not part of the EU, it's an advantage to be able to submit at any time," Meyer stated.
Patient Recruitment and Site Selection
The DACH region faces certain recruitment challenges, though industry experts have identified effective strategies to address them. While progress has been made in implementing electronic health records and digital solutions, Meyer highlighted the need for enhanced patient identification using real-world evidence during recruitment.
Sauerland shared insights on successful recruitment strategies, emphasizing the importance of looking beyond traditional academic centers: "What we saw in the past is in small towns in North-East Germany...had very good recruitment and good compliance sites and patients. This is important for our device; we need compliant patients that use it right."
Future Outlook and Opportunities
Enrico Perfler, founder of medtech CRO 1MED (搜索), maintains that the DACH region remains "very attractive" despite regulatory complexities. The region's success in clinical trials increasingly depends on strategic partnerships, educational initiatives, and strong collaboration between sponsors, CROs, and clinical trial sites.
The evolution of the clinical trial landscape in the DACH region demonstrates a delicate balance between regulatory compliance and innovation, with stakeholders adapting to maximize opportunities while navigating regulatory requirements.